Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › Levo-α-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial

Publication

Levo-α-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial

Wieneke, H.; Conrads, H.; Wolstein, Jörg; u. a. (2009): Levo-α-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial, in: European Journal of Medical Research, London: BioMed Central, Jg. 14, Nr. 7, S. 7–12, doi: 10.1186/2047-783X-14-1-7.

Details

Faculty/Chair
Author
Wieneke, H.
Conrads, H.
Breuckmann, F.
Gastpar, M.
Erbel, R.
Scherbaum, N.
Title of the Journal
European Journal of Medical Research
Corporate Body
Deutsche AIDS-Gesellschaft
Publisher Information
BioMed Central : London
Year of publication
2009
Volume
14
Issue
7
Language
English
DOI
Abstract

Background

Due to potential proarrhythmic side-effects levo-α-Acetylmethadol (LAAM) is currently not available in EU countries as maintenance drug in the treatment of opiate addiction. However, recent studies and meta-analyses underline the clinical advantages of LAAM with respect to the reduction of heroin use. Thus a reappraisal of LAAM has been demanded. The aim of the present study was to evaluate the relative impact of LAAM on QTc-interval, as a measure of pro-arrhythmic risk, in comparison to methadone, the current standard in substitution therapy.

Methods

ECG recordings were analysed within a randomized, controlled clinical trial evaluating the efficacy and tolerability of maintenance treatment with LAAM compared with racemic methadone. Recordings were done at two points: 1) during a run-in period with all patients on methadone and 2) 24 weeks after randomisation into methadone or LAAM treatment group. These ECG recordings were analysed with respect to QTc-values and QTc-dispersion. Mean values as well as individual changes compared to baseline parameters were evaluated. QTc-intervals were classified according to CPMP-guidelines.

Results

Complete ECG data sets could be obtained in 53 patients (31 LAAM-group, 22 methadone-group). No clinical cardiac complications were observed in either group. After 24 weeks, patients receiving LAAM showed a significant increase in QTc-interval (0.409 s ± 0.022 s versus 0.418 s ± 0.028 s, p = 0.046), whereas no significant changes could be observed in patients remaining on methadone. There was no statistically significant change in QTc-dispersion in either group. More patients with borderline prolonged and prolonged QTc-intervals were observed in the LAAM than in the methadone treatment group (n = 7 vs. n = 1; p = 0.1).

Conclusions

In this controlled trial LAAM induced QTc-prolongation in a higher degree than methadone. Given reports of severe arrhythmic events, careful ECG-monitoring is recommended under LAAM medication.

Keywords
LAAM
methadone
opiate addiction
cardiac arrhythmia
QTc-interval
Open Access Journal
no
Type
Article
URI
Activation date
2018-11-23, 2018-11-23

Permalink: https://fis.uni-bamberg.de/handle/uniba/44810 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.